1. Home
  2. LOAN vs ACET Comparison

LOAN vs ACET Comparison

Compare LOAN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

N/A

Current Price

$4.29

Market Cap

51.9M

Sector

Real Estate

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.70

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LOAN
ACET
Founded
1989
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
69.6M
IPO Year
1999
2017

Fundamental Metrics

Financial Performance
Metric
LOAN
ACET
Price
$4.29
$7.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
20.8K
161.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.33%
N/A
EPS Growth
2.08
59.82
EPS
0.35
N/A
Revenue
$9,688,641.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$12.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$0.45
52 Week High
$6.05
$9.05

Technical Indicators

Market Signals
Indicator
LOAN
ACET
Relative Strength Index (RSI) 25.71 57.76
Support Level N/A $7.70
Resistance Level $4.59 $8.46
Average True Range (ATR) 0.07 0.46
MACD -0.01 -0.01
Stochastic Oscillator 0.00 96.30

Price Performance

Historical Comparison
LOAN
ACET

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: